Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics

HONG KONG and GERMANTOWN, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ — Sirnaomics Ltd. (the “Company”, together with its subsidiaries, the “Group” or “Sirnaomics”; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi…